The online reference source for the interventional NeuroRadiology, Neurology and NeuroSurgery community
Nashville, TN, May 11, 2021 Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR(1) acute ischemic stroke FDA IDE clinical trial utilizing the NeVaTM thrombectomy technology platform. With twenty participating stroke treatment centers, enrollment is expected to be completed in early 2022.
May 12, 2021
NETANYA, Israel, April 29, 2021 - Perflow Medical, a private, Israeli-based innovator for neurovascular treatments, today announced the first successful clinical use of the Stream™17 Dynamic Neuro-Thrombectomy Net, a lower profile device designed for more tortuous anatomy, to effectively treat hemorrhagic and ischemic stroke patients.
April 29, 2021
Nashville, TN, April 28, 2021, Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL1 clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), has been completed.
April 28, 2021
NETANYA, Israel, March 10, 2021 /PRNewswire/ -- Perflow Medical, a private, Israeli-based innovator of solutions for neurovascular treatment, today announced it has launched to the European market the Cascade™ 17 Non-Occlusive Remodeling Net.
March 10, 2021
FREMONT, Calif. and OXFORD, United Kingdom, Feb. 11, 2021 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company, today announced that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Contour Neurovascular System™.
February 12, 2021
Bochum, 10th February 2021. Despite a challenging year 2020, Phenox GmbH is pursuing its strategic plans in strengthening the footprint in key markets across Europe. As part of this strategy and in the light of Brexit, Phenox has taken the decision to open a UK entity materialising in its new office south of Birmingham.
February 11, 2021
Nashville, TN, January 28, 2021 Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels. The new CE approval expands the NeVa™ neuro-thrombectomy portfolio. Vesalio’s Drop ZoneTM technology, designed to remove the full spectrum of clots from vascular anatomy, has been acclaimed for consistently achieving high first-pass rates, a key parameter associated with better patient outcomes in stroke.
February 1, 2021
Aliso Viejo, CA. – January 12, 2021 – MicroVention, Inc., a U.S.-based subsidiary of Terumo and a global neurovascular company, announced today the FDA Approval of the PMA Supplement for the WEB 17 System, a new addition to the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms. The WEB 17 System, designed with the latest microbraid technology, features a lower profile delivery system compatible with the VIA™ 17 microcatheter and includes additional device configurations.
January 14, 2021
Nashville, TN, December 7, 2020 - Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform. Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic stroke.
December 7, 2020
IRVINE, CA – October 7, 2020 – CERENOVUS, part of Johnson & Johnson Medical Devices Companies*, today announced the European launch of CERENOVUS NIMBUS™, designed to remove tough clots for successful revascularization in patients with acute ischemic stroke caused by a large vessel occlusion.
October 7, 2020